1. Home
  2. ARGX vs OXY Comparison

ARGX vs OXY Comparison

Compare ARGX & OXY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARGX
  • OXY
  • Stock Information
  • Founded
  • ARGX 2008
  • OXY 1920
  • Country
  • ARGX Netherlands
  • OXY United States
  • Employees
  • ARGX N/A
  • OXY N/A
  • Industry
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • OXY Oil & Gas Production
  • Sector
  • ARGX Health Care
  • OXY Energy
  • Exchange
  • ARGX Nasdaq
  • OXY Nasdaq
  • Market Cap
  • ARGX 44.2B
  • OXY 47.3B
  • IPO Year
  • ARGX 2017
  • OXY N/A
  • Fundamental
  • Price
  • ARGX $763.49
  • OXY $46.01
  • Analyst Decision
  • ARGX Strong Buy
  • OXY Hold
  • Analyst Count
  • ARGX 19
  • OXY 20
  • Target Price
  • ARGX $765.72
  • OXY $52.15
  • AVG Volume (30 Days)
  • ARGX 365.8K
  • OXY 7.9M
  • Earning Date
  • ARGX 10-30-2025
  • OXY 08-06-2025
  • Dividend Yield
  • ARGX N/A
  • OXY 2.09%
  • EPS Growth
  • ARGX N/A
  • OXY N/A
  • EPS
  • ARGX 18.75
  • OXY 1.71
  • Revenue
  • ARGX $3,120,821,000.00
  • OXY $27,150,000,000.00
  • Revenue This Year
  • ARGX $77.61
  • OXY $1.40
  • Revenue Next Year
  • ARGX $30.50
  • OXY $2.13
  • P/E Ratio
  • ARGX $36.76
  • OXY $26.89
  • Revenue Growth
  • ARGX 88.04
  • OXY 0.10
  • 52 Week Low
  • ARGX $510.06
  • OXY $34.79
  • 52 Week High
  • ARGX $779.03
  • OXY $56.49
  • Technical
  • Relative Strength Index (RSI)
  • ARGX 78.99
  • OXY 53.09
  • Support Level
  • ARGX $697.87
  • OXY $44.98
  • Resistance Level
  • ARGX $779.03
  • OXY $46.31
  • Average True Range (ATR)
  • ARGX 15.77
  • OXY 1.17
  • MACD
  • ARGX 4.30
  • OXY -0.12
  • Stochastic Oscillator
  • ARGX 87.10
  • OXY 37.31

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

About OXY Occidental Petroleum Corporation

Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,327 thousand barrels of oil equivalent per day in 2024 at a ratio of roughly 52% oil and natural gas liquids and 48% natural gas.

Share on Social Networks: